Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Regeneron from a Buy to a Hold in a report released Saturday.
• Despite that downgrade, analysts collectively rate REGN a Moderate Buy (2 Strong Buy, 16 Buy, 9 Hold) with a consensus target price of $811.96.
• Regeneron recently beat quarterly estimates—$11.44 EPS vs. $10.74 expected and $3.88B revenue—and insiders sold roughly 3,774 shares (~$2.94M) last quarter while institutional investors own 83.31% of the stock.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

REGN has been the topic of a number of other research reports. Evercore raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research note on Thursday, January 22nd. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a "sector perform" rating in a research note on Monday, March 2nd. Piper Sandler assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They set an "overweight" rating and a $875.00 target price on the stock. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating on the stock in a research note on Wednesday. Finally, Oppenheimer restated an "outperform" rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $811.96.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $748.87 on Friday. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11. The stock has a market cap of $79.17 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 2.04 and a beta of 0.40. The company's 50 day moving average is $767.42 and its two-hundred day moving average is $719.00. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter last year, the business earned $12.07 EPS. The firm's revenue was up 2.5% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,774 shares of company stock worth $2,942,738 over the last quarter. Insiders own 7.02% of the company's stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. Purpose Unlimited Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $87,000. Rockefeller Capital Management L.P. increased its position in Regeneron Pharmaceuticals by 4.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 27,053 shares of the biopharmaceutical company's stock worth $20,882,000 after purchasing an additional 1,211 shares during the last quarter. World Investment Advisors increased its position in Regeneron Pharmaceuticals by 56.5% in the fourth quarter. World Investment Advisors now owns 798 shares of the biopharmaceutical company's stock worth $616,000 after purchasing an additional 288 shares during the last quarter. PeakShares LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $1,102,000. Finally, Pure Financial Advisors LLC increased its position in Regeneron Pharmaceuticals by 35.4% in the fourth quarter. Pure Financial Advisors LLC now owns 497 shares of the biopharmaceutical company's stock worth $384,000 after purchasing an additional 130 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.